STOCK TITAN

MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced its participation in the Lytham Partners Fall 2021 Investor Conference on October 5, 2021, at 11:45 am ET. CEO Michael Castagna, PharmD, will represent the company during the event. Interested parties can access a live webcast of the presentation through the Company’s website. MannKind focuses on developing inhaled therapeutic products, including Afrezza®, the only inhaled ultra rapid-acting insulin available in the U.S. The webcast replay will be available for 14 days post-event.

Positive
  • None.
Negative
  • None.

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 11:45 am (ET). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.

Interested parties can access a link to the live webcast of the presentations from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations.  The webcast replay may be accessed at the same location for 14 days following the live presentation.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com


FAQ

When is MannKind Corporation participating in the Lytham Partners Fall 2021 Investor Conference?

MannKind Corporation will participate in the Lytham Partners Fall 2021 Investor Conference on October 5, 2021, at 11:45 am ET.

Who will represent MannKind Corporation at the investor conference?

CEO Michael Castagna, PharmD, will represent MannKind Corporation at the investor conference.

How can I access the MannKind Corporation investor conference webcast?

The webcast can be accessed through the Events & Presentations section of MannKind Corporation's website.

What is Afrezza from MannKind Corporation?

Afrezza is the only inhaled ultra rapid-acting mealtime insulin available in the United States, developed by MannKind Corporation.

How long will the MannKind Corporation webcast replay be available?

The webcast replay will be available for 14 days following the live presentation.

Mannkind Corporation

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Stock Data

1.87B
270.76M
1.83%
56.64%
15.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DANBURY